Short Interest in Humacyte, Inc. (NASDAQ:HUMA) Grows By 34.9%

Humacyte, Inc. (NASDAQ:HUMA) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 29,620,000 shares, a growth of 34.9% from the December 15th total of 21,960,000 shares. Approximately 28.4% of the company’s shares are short sold. Based on an average daily volume of 4,700,000 shares, the days-to-cover ratio is currently 6.3 days.

Insider Buying and Selling at Humacyte

In other news, CEO Laura E. Niklason sold 811,172 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the sale, the chief executive officer now directly owns 2,419,712 shares of the company’s stock, valued at approximately $10,743,521.28. The trade was a 25.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock worth $6,606,799 over the last quarter. 11.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently modified their holdings of HUMA. Brookstone Capital Management purchased a new position in Humacyte in the fourth quarter valued at $56,000. ACT Wealth Management LLC purchased a new position in shares of Humacyte in the 4th quarter valued at about $57,000. Concurrent Investment Advisors LLC acquired a new stake in shares of Humacyte during the 3rd quarter worth about $75,000. FORA Capital LLC purchased a new stake in Humacyte during the third quarter worth approximately $96,000. Finally, Insigneo Advisory Services LLC acquired a new position in Humacyte in the third quarter valued at approximately $109,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on HUMA shares. D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Monday, January 13th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 target price on shares of Humacyte in a report on Friday, September 20th. TD Cowen reiterated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the company a “neutral” rating in a research note on Friday, October 18th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a report on Friday, December 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $13.71.

Humacyte Stock Performance

HUMA stock opened at $4.41 on Friday. Humacyte has a fifty-two week low of $2.53 and a fifty-two week high of $9.97. The company’s 50 day moving average price is $4.58 and its 200 day moving average price is $5.66. The firm has a market capitalization of $555.04 million, a price-to-earnings ratio of -3.29 and a beta of 1.32.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.